Skip to content
★ Sign in to follow
Bloomage BioTechnology Corporation Limited logo

Bloomage BioTechnology Corporation Limited Stock: price and insider trades · China

华熙生物

CN·Mcap CN¥16.4BHealth Care

No insider purchase over the last 90 days. The latest, by 华熙昕宇投资有限公司, was filed 05 Sept 2025.

Bloomage BioTechnology Corporation Limited: what insiders have been doing

Bloomage BioTechnology Corporation Limited, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). Nothing new has been filed by managers of Bloomage BioTechnology Corporation Limited in twelve months, the latest record being from 5 September 2025.

Looking back to 2022, when coverage begins, insiders filed 2 purchases and 4 sales.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Insider Decl.
6
Thresholds
n/a
Buy Volume
€9M
2 ops. · all time
Sell Volume
€449,625
4 ops. · all time

Who traded when

BuySale
华熙昕宇投资有限公司1 buy

Since the insiders bought

  • Filed 05 Sept 2025 · 429 days ago · €9.4M
    -23.6%
    Entry CN¥60.00 · Close at T+90 CN¥45.84
  • Filed 05 Sept 2024 · 794 days ago · €1,242
    +23.2%
    Entry CN¥48.72 · Close at T+365 CN¥60.00

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Bloomage BioTechnology Corporation Limited Hold (neutral), based on 6 analysts. Average price target: CN¥35.70.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 13,766 of 26,914 companies
50.8
score / 100
Value
36
Quality
66
FCF yld1.8%
Earn yld1.8%
EV/EBITDA24.0x
ROE3.2%
Gross mgn70%
Net mgn7.0%
Debt/EBITDA0.5x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥34.00
Analyst consensus
6 analysts
Hold
CN¥23.00Target CN¥35.70(+5%)CN¥52.20
Income statement
RevenueCN¥4.2B
Gross profitCN¥3B70% margin
EBITDACN¥698M17% margin
Net incomeCN¥292.1M6.1% margin
Valuation
PER (trailing)70.8x
PER (forward)39.1x
P/Book2.3x
Beta0.45
Balance sheet & cash
Market capCN¥16.4B
Total debtCN¥341.4M
Free Cash FlowCN¥301.8M
Debt / Equity7%
Profitability & ownership
ROE3.2%
ROA0.7%
% insiders61.8%
% institutions9.7%
Last declaration on 5 September 2025
Declarations6 total
  • ▲
    Related company / holdingExecutives
    78M CNY30SSE
    1,379,241 shares100.0% of flowA股XSHGSSE:173000009497862370
    Canonical exit: 4 Dec 2025 (T+90)
  • ▲
    核心技术人员Executives
    9,792 CNY10SSE
    200 shares100.0% of flowA股XSHGSSE:173000008086658800
    Canonical exit: 4 Dec 2024 (T+90)
  • ▼
    核心技术人员Executives
    112,199 CNY10SSE
    1,456 shares100.0% of flowA股XSHGSSE:173000007028544160
  • ▼
    核心技术人员Executives
    200,692 CNY7SSE
    2,081 shares54.1% of flowA股XSHGSSE:173000006815366370
  • ▼
    核心技术人员Executives
    171,511 CNY7SSE
    1,789 shares45.9% of flowA股XSHGSSE:173000006812338270
  • ▼
    核心技术人员Executives
    3M CNY10SSE
    25,000 shares100.0% of flowA股XSHGSSE:173000006060669400

6 of 6 declarations

About Bloomage BioTechnology Corporation Limited

华熙生物 is a company in the health and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the research and development of biological and pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations